DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Efficacy of Hormone Therapy With Letrozole in Postmenopausal Women With Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: letrozole

First Posted Date: 2006-05-26

Last Posted Date: 2017-02-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 300

Registration Number: NCT00330317

Locations: 🇬🇧
Novartis Investigative Site, West Smithfield, United Kingdom

Safety and Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Letrozole

First Posted Date: 2006-05-25

Last Posted Date: 2017-02-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 200

Registration Number: NCT00329940

Locations: 🇫🇷
Novartis Investigative Site, Saint Cloud, France

Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS

Phase 2

Terminated

Conditions: Cryptococcal Meningitis

Interventions: Drug: Mycograb
Drug: placebo

First Posted Date: 2006-05-10

Last Posted Date: 2008-12-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 3

Registration Number: NCT00324025

Locations: 🇺🇸
University of Alabama School of Medicine, Birmingham, Alabama, United States
🇺🇸
Department of Medicine/Infectious Disease, MC 7881, University of Texas Health Science Center, San Antonio, Texas, United States

Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Zoledronic acid
Drug: Placebo

First Posted Date: 2006-05-03

Last Posted Date: 2014-08-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 416

Registration Number: NCT00320710

Locations: 🇺🇸
Greenbaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
U of Pittsburgh Cancer Institute Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸
Frederick Memorial Hospital, Frederick, Maryland, United States

and more 89 locations

Efficacy and Safety of Low-molecular Weight Heparin for Thromboprophylaxis in Acutely Ill Medical Patients

Phase 3

Completed

Conditions: Embolism

Interventions: Drug: Certoparin
Drug: Heparin

First Posted Date: 2006-04-06

Last Posted Date: 2017-02-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 342

Registration Number: NCT00311753

Locations: 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland

Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes

Phase 3

Completed

Conditions: Genital Herpes

Interventions: Drug: Famciclovir
Drug: Valacyclovir
Drug: Placebo matching valacyclovir
Drug: Placebo matching famciclovir

First Posted Date: 2006-03-24

Last Posted Date: 2011-06-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1179

Registration Number: NCT00306787

Locations: 🇺🇸
Providence Clinical Research, Burbank, California, United States
🇺🇸
Women's Medical Research Group, LLC, Clearwater, Florida, United States
🇺🇸
UNC Clinical Research., Raleigh, North Carolina, United States

and more 49 locations

A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma

Phase 1

Completed

Conditions: Metastatic Melanoma

Interventions: Drug: RAF265

First Posted Date: 2006-03-20

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 104

Registration Number: NCT00304525

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. Medical Oncology, Baltimore, Maryland, United States
🇺🇸
Georgia Regents University Cancer Clinical Research Unit, Augusta, Georgia, United States
🇺🇸
University of Pennsylvania Health System Dept of Hospital of UnivofPenn, Philadelphia, Pennsylvania, United States

and more 8 locations

Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients

Phase 2

Completed

Conditions: Anemia
Hemosiderosis

Interventions: Drug: Deferasirox

First Posted Date: 2006-03-16

Last Posted Date: 2011-05-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 184

Registration Number: NCT00303329

Locations: 🇺🇸
Childres's Hospital Boston, Boston, Massachusetts, United States
🇺🇸
Stanford Hospital, Stanford, California, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

and more 3 locations

Safety of TKI258 in Advanced/Metastatic Melanoma Subjects

Phase 1

Completed

Conditions: Melanoma

Interventions: Drug: TKI258

First Posted Date: 2006-03-16

Last Posted Date: 2021-03-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 47

Registration Number: NCT00303251

Locations: 🇺🇸
James Graham Brown Cancer Center, Louisville, Kentucky, United States
🇺🇸
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸
MD Anderson Cancer, Houston, Texas, United States

Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia

Conditions: Chronic Myeloid Leukemia

First Posted Date: 2006-03-13

Last Posted Date: 2011-08-26

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT00302016

Locations: 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
Stroger Cook County Hospital, Chicago, Illinois, United States
🇺🇸
Swedish Cancer Institute, Seattle, Washington, United States

and more 56 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy